1. Home
  2. BNTC

BNTC

Benitec Biopharma Inc.

Logo Benitec Biopharma Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-17-2024 11:01am EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.

Founded: 1995 Country:
United States
United States
Employees: N/A City: HAYWARD
Market Cap: 14.3M IPO Year: N/A
Target Price: $10.00 AVG Volume (30 days): 18.2K
Analyst Decision: Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.07 EPS Growth: N/A
52 Week Low/High: $1.86 - $9.01 Next Earning Date: 05-13-2024
Revenue: $61,000 Revenue Growth: -1.61%
Revenue Growth (this year): 36% Revenue Growth (next year): 650.00%

Share on Social Networks: